Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers-Reference-Cited by-同舟云学术

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Published:2015-02-16 Issue:3 Volume:21 Page:231-238
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Bitler Benjamin G,Aird Katherine M,Garipov Azat,Li Hua,Amatangelo Michael,Kossenkov Andrew V,Schultz David C,Liu Qin,Shih Ie-Ming,Conejo-Garcia Jose R,Speicher David W,Zhang Rugang

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.3799.pdf

Reference39 articles.

1. Garraway, L.A. & Lander, E.S. Lessons from the cancer genome. Cell 153, 17–37 (2013).

2. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).

3. Wilson, B.G. & Roberts, C.W. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481–492 (2011).

4. Wiegand, K.C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532–1543 (2010).

5. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228–231 (2010).

Cited by 542 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First description of a primary SMARCA4-deficient carcinoma of the salivary glands;Human Pathology Reports;2024-11

2. Epigenetics and immunotherapy in colorectal cancer: progress and promise;Clinical Epigenetics;2024-09-10

3. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes;Cancers;2024-09-03

4. Bisphenol S (BPS) induces glioblastoma progression via regulation of EZH2-mediated PI3K/AKT/mTOR pathway in U87-MG cells;Toxicology;2024-09

5. DNMT3A loss drives a HIF-1-dependent synthetic lethality to HDAC6 inhibition in non-small cell lung cancer;Acta Pharmaceutica Sinica B;2024-09